Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to be submitting our NDA for VivaGel® BV. Starpharma is one of very few Australian companies to have achieved an NDA submission. It is very satisfying strategically that we have retained the commercial rights to VivaGel® BV, while developing the product from discovery through to the successful phase 3 trials and NDA submission – in doing so we’ve maximised its commercial value.”
I like the last bit ... hehe
Ann: NDA submission for VivaGel BV in the US, page-5
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $38.11K | 389.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20455 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 38876 | 3 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |